Compare TG Therapeutics Inc (TGTX) vs Block Inc (XYZ) Price & Performance

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.

XYZ stock trades at $80.10, down 3.21% over 24 hours, with a bearish technical signal and support near $77. Recent earnings show mixed results, beating estimates in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is modest, with net income margin at 1.43% for 2025. The company is expanding into financial services, applying for a national trust bank charter to offer custody services, as reported by Business Wire on September 8, 2026.

The outlook is cautiously optimistic, with a consensus price target of $100.20 implying 25% upside, supported by 76% buy ratings from analysts. Risks include high P/E ratio of 143.04, regulatory hurdles for new banking initiatives, and volatile cash flows, with net cash flow negative $749 million in 2025. Institutional interest remains strong, with recent buying by Freestone Grove Partners LP noted in a Form 13F filing on August 30, 2026.